Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01865812 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis
A Phase 2 study, sponsored by Intercept Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01865812 is a Phase 2 study that has completed, run by Intercept Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT01865812, a Phase 2 study, has completed, sponsored by Intercept Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if OCA had an effect on cholesterol levels in the blood in participants with primary biliary cirrhosis (PBC).
Interventions
- DRUG Obeticholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2016-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01865812
The ClinicalTrials.gov registry entry for NCT01865812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Obeticholic Acid is the first listed.
NCT01865812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01865812 about?
NCT01865812 is a clinical study titled "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis". The purpose of this study was to determine if OCA had an effect on cholesterol levels in the blood in participants with primary biliary cirrhosis (PBC).
What is the current status of trial NCT01865812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2013-12-03. Estimated completion is 2016-09-12.
What interventions are being tested in trial NCT01865812?
The interventions under investigation include: Obeticholic Acid (DRUG).
Who is sponsoring clinical trial NCT01865812?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.